1.46
price up icon0.00%   0.00
after-market Handel nachbörslich: 1.49 0.03 +2.05%
loading
Schlusskurs vom Vortag:
$1.46
Offen:
$1.45
24-Stunden-Volumen:
749.82K
Relative Volume:
0.84
Marktkapitalisierung:
$158.09M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-2.8077
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+15.87%
1M Leistung:
+9.77%
6M Leistung:
-64.13%
1J Leistung:
+39.05%
1-Tages-Spanne:
Value
$1.39
$1.475
1-Wochen-Bereich:
Value
$1.27
$1.56
52-Wochen-Spanne:
Value
$0.9903
$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name
Firmenname
Aclaris Therapeutics Inc
Name
Telefon
484-324-7933
Name
Adresse
701 LEE ROAD, WAYNE, PA
Name
Mitarbeiter
64
Name
Twitter
@aclaristx
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
ACRS's Discussions on Twitter

Vergleichen Sie ACRS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACRS
Aclaris Therapeutics Inc
1.46 136.43M 27.08M -37.00M -18.46M -0.52
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-18 Fortgesetzt Cantor Fitzgerald Overweight
2024-12-23 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-20 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-11-19 Hochstufung BTIG Research Neutral → Buy
2024-11-19 Hochstufung Jefferies Hold → Buy
2024-11-19 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-18 Hochstufung Piper Sandler Neutral → Overweight
2024-01-22 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-13 Herabstufung William Blair Outperform → Mkt Perform
2023-10-03 Eingeleitet Evercore ISI Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-01 Eingeleitet Goldman Buy
2022-10-06 Eingeleitet BTIG Research Buy
2021-07-23 Fortgesetzt Jefferies Buy
2021-06-15 Eingeleitet Piper Sandler Overweight
2021-04-21 Eingeleitet H.C. Wainwright Buy
2019-10-22 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-27 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-05-06 Eingeleitet SVB Leerink Outperform
2018-03-28 Fortgesetzt Leerink Partners Outperform
2018-02-09 Eingeleitet Guggenheim Buy
2017-06-16 Eingeleitet Cantor Fitzgerald Overweight
2016-11-29 Eingeleitet Leerink Partners Outperform
2016-09-30 Eingeleitet JMP Securities Mkt Outperform
2016-06-10 Eingeleitet Guggenheim Buy
2015-11-02 Eingeleitet Citigroup Buy
2015-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten

pulisher
10:31 AM

What is Wedbush’s Forecast for ACRS Q2 Earnings? - Defense World

10:31 AM
pulisher
May 30, 2025

Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 - MSN

May 30, 2025
pulisher
May 29, 2025

Millennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 29, 2025
pulisher
May 29, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Wedbush - Defense World

May 29, 2025
pulisher
May 28, 2025

Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Aclaris Therapeutics Secures Double Speaking Slots at Major June Healthcare Conferences - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Wedbush sets Aclaris stock Outperform with $8 target By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Wedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform Recommendation - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Aclaris Therapeutics (ACRS) Receives Outperform Rating from Wedbush | ACRS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 28, 2025
pulisher
May 28, 2025

Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbush | ACRS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Aclaris Therapeutics (ACRS) Receives Positive Rating from Wedbush | ACRS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - The Globe and Mail

May 27, 2025
pulisher
May 25, 2025

Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail

May 25, 2025
pulisher
May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World

May 21, 2025
pulisher
May 18, 2025

HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World

May 17, 2025
pulisher
May 16, 2025

Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN

May 16, 2025
pulisher
May 16, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World

May 16, 2025
pulisher
May 14, 2025

Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN

May 14, 2025
pulisher
May 13, 2025

Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com

May 13, 2025
pulisher
May 12, 2025

Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN

May 12, 2025
pulisher
May 12, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN

May 12, 2025
pulisher
May 11, 2025

Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World

May 11, 2025
pulisher
May 10, 2025

Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Purchases New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 10, 2025
pulisher
May 10, 2025

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire

May 10, 2025
pulisher
May 10, 2025

Scotiabank Adjusts Price Target for Aclaris Therapeutics (ACRS) - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Aclaris Therapeutics to Participate in the HC Wainwright 'HCW@Home” Series - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire Inc.

May 09, 2025
pulisher
May 09, 2025

Mariner LLC Sells 10,327 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 09, 2025
pulisher
May 09, 2025

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 09, 2025
pulisher
May 09, 2025

Aclaris: Q1 Earnings Snapshot - CT Insider

May 09, 2025
pulisher
May 08, 2025

Aclaris Therapeutics Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics Reports Q1 2025 Financial Results and Corporate Update with Focus on Immuno-Inflammatory Developments and Extended Cash Runway through 2028 - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Hims & Hers Has a Superpower in Healthcare - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Here's Why I'm Still Buying SoFi Hand Over Fist in 2025 - The Globe and Mail

May 08, 2025
pulisher
May 07, 2025

Aclaris Therapeutics Inc (ACRS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX

May 07, 2025
pulisher
May 06, 2025

Invesco Ltd. Invests $28,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

May 06, 2025
pulisher
May 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 04, 2025

Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):